Across TCGA pan-cancer cohorts, CSTA Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CSTA data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher CSTA Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CSTA expression acts as an unfavorable survival marker.
COAD and SKCM are the cancer types where CSTA Mutation most reproducibly stratifies survival.